Outbreaks of novel coronavirus disease (COVID‐19) began in Wuhan, China, in December 2019. South Korea experienced one of the earliest outbreaks of COVID‐19. Until April 4, 2020, 455 032 people were tested, and 10 156 were diagnosed as COVID‐19 positive. It is rapidly spreading regardless of nation, but there is still no specific treatment regimen, especially for the immunocompetent...

Yaerim Kim et al.
American Journal of Transplantation 2020; AOP: 10.1111/ajt.15947
Lire la suite

While donation after brain death (DBD) continues to form the basis for the majority of organ transplant activity globally, particularly among Western countries, donation after circulatory death (DCD) has increased considerably in recent years and has come to represent 30% of all donation activity in Belgium, almost 40% in the United Kingdom (UK), and over 50% in The Netherlands [1]. Even in Spain,...

Amelia J. Hessheimer et al.
Transplant International 2020; AOP: 10.1111/tri.13619
Lire la suite

PPCA in the organ donor has historically been considered detrimental to overall donor quality in LT. Prolonged periods of cardiopulmonary arrest prior to organ procurement raise concern for ischemic injury to the liver that may compromise function of the graft. However, liver grafts from donors with a history of PPCA are now in widespread use, with research in adult populations demonstrating the safety...

Joel R. Schroering et al.
Pediatric Transplantation 2020; AOP: 10.1111/petr.13701
Lire la suite

Hepatitis B virus (HBV) infection still represents a major health concern, with a prevalence of 2% in Western countries and 8% in West Africa. Chronic HBV infection shows a high morbidity and mortality due to severe complications such as liver cirrhosis and hepatocellular carcinoma (HCC). Liver transplantation (LT) is the only curative treatment for patients suffering from the end stage of HBV‐associated...

Eva Maria Dobrindt et al.
Transplant Infectious Disease 2020; AOP: 10.1111/tid.13303
Lire la suite